Table 4.

LS mean difference for treatment (MSG v. Placebo), categories, and their interaction within anxiety (GAD-7).

	Est	SE	t-value (DF=35)	p- value
CM
Placebo v. MSG	−0.25	0.69	−0.36	0.723
GAD category
Min/mild v. moderate	0.67	2.03	0.33	0.743
Min/mild v. severe	7.66	1.51	5.08	<0.001
Moderate v. severe	−6.99	2.15	−3.24	0.003
CM*GAD category
Placebo v. MSG: within category
Min/mild	−1.30	0.78	−1.66	0.107
Moderate	−2.04	1.62	−1.26	0.217
Severe	2.60	1.15	2.26	0.030
Within placebo
Min/mild v. moderate	1.04	2.23	0.47	0.644
Min/mild v. severe	5.71	1.66	3.44	0.002
Moderate v. severe	−4.67	2.37	−1.97	0.057
Within MSG
Min/mild v. moderate	0.30	2.23	0.13	0.895
Min/mild v. severe	9.61	1.66	5.79	<0.001
Moderate v. severe	−9.31	2.37	−3.92	<0.001
Placebo v. MSG: between categories
Min/mild v. moderate	−1.00	2.20	−0.45	0.653
Min/mild v. severe	8.31	1.66	5.00	<0.001
Moderate v. severe	7.27	2.37	3.06	0.004
MSG v. placebo: between categories
Min/mild v. moderate	−2.34	2.21	−1.06	0.296
Min/mild v. severe	−7.01	1.66	−4.22	<0.001
Moderate v. severe	−6.71	2.37	−2.83	0.008

CM, Challenge Materials (0, placebo, 1, MSG). Bold, significant at the p <0.05. Reference category; CM, Placebo (0); GAD Category, Minimal/mild (1).

^*indicates interaction.